Neuraxis, Inc.(NRXS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRXS Neuraxis, Inc.

Market Closed 01-23 16:00:00 EST

4.86

+0.23

+4.97%

盘后4.92

+0.06+1.23%

19:10 EST

High4.99	Low4.66	Vol51.48K
Open4.66	D1 Closing4.63	Amplitude7.13%
Mkt Cap51.77M	Tradable Cap37.26M	Total Shares10.65M
T/O248.48K	T/O Rate0.67%	Tradable Shares7.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRXS","market":"US","secType":"STK","nameCN":"Neuraxis, Inc.","latestPrice":4.86,"timestamp":1769202000000,"preClose":4.63,"halted":0,"volume":51476,"hourTrading":{"tag":"盘后","latestPrice":4.92,"preClose":4.86,"latestTime":"19:10 EST","volume":169,"amount":831.3327,"timestamp":1769213432142,"change":0.06,"changeRate":0.012346,"amplitude":0.012346},"delay":0,"changeRate":0.04967602591792666,"floatShares":7666700,"shares":10652812,"eps":-1.009811,"marketStatus":"Market Closed","change":0.23,"latestTime":"01-23 16:00:00 EST","open":4.66,"high":4.99,"low":4.66,"amount":248482.733732,"amplitude":0.071274,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.009811,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":7,"adr":0,"listingDate":1691553600000,"exchange":"AMEX","adjPreClose":4.63,"postHourTrading":{"tag":"盘后","latestPrice":4.92,"preClose":4.86,"latestTime":"19:10 EST","volume":169,"amount":831.3327,"timestamp":1769213432142,"change":0.06,"changeRate":0.012346,"amplitude":0.012346},"volumeRatio":0.4349824743963133},"requestUrl":"/m/hq/s/NRXS/wiki","defaultTab":"wiki","newsList":[{"id":"2601243362","title":"Neuraxis announces Category I CPT code for PENFS now in effect","url":"https://stock-news.laohu8.com/highlight/detail?id=2601243362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601243362?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:38","pubTimestamp":1767879498,"startTime":"0","endTime":"0","summary":"NeurAxis (NRXS) announced that the Category I CPT code for Percutaneous Electrical Nerve Field Stimulation, PENFS, is now in effect, completing a s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuraxis-announces-category-i-cpt-code-for-penfs-now-in-effect-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuraxis-announces-category-i-cpt-code-for-penfs-now-in-effect-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4215","BK4082","BK4585","NRXS","CPT"],"gpt_icon":0},{"id":"2601852364","title":"NeurAxis Inc. to Present at Lytham Partners Healthcare Investor Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2601852364","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601852364?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877213,"startTime":"0","endTime":"0","summary":"NeurAxis Inc. management will present at the Lytham Partners Healthcare Investor Summit on Thursday, January 15, 2026, at 9:30 a.m. ET. The event will be accessible via webcast on the conference home page and a replay will also be available.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire  on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL3JpvVC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","NRXS","LU2095319765.USD","BK4588","BK4082","SG9999014039.USD","BK4112","NDAQ","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014021.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2595675300","title":"NeurAxis Inc. Director Aharon Gil Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595675300","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595675300?lang=en_us&edition=fundamental","pubTime":"2025-12-30 06:12","pubTimestamp":1767046353,"startTime":"0","endTime":"0","summary":"Gil Aharon, a director, reported the acquisition of common shares of NeurAxis Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDLq0S1D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NeurAxis Inc. Director Aharon Gil Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2593007439","title":"Neuraxis Is Maintained at Buy by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2593007439","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593007439?lang=en_us&edition=fundamental","pubTime":"2025-12-23 00:36","pubTimestamp":1766421360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 22, 2025 11:36 ET (16:36 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS"],"gpt_icon":0},{"id":"2588247317","title":"NeurAxis Secures VA Federal Supply Schedule Contract for IB-Stim","url":"https://stock-news.laohu8.com/highlight/detail?id=2588247317","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588247317?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590421,"startTime":"0","endTime":"0","summary":"NeurAxis Inc. has announced that it has been awarded a Veterans Affairs  Federal Supply Schedule  contract, effective December 1, 2025. The first product listed under this contract is IB-Stim, a drug-free treatment for functional abdominal pain in patients aged 8 years and older. This FSS contract establishes NeurAxis as a federal contractor and provides a commercial pathway into the VA health system. The company expects that the VA award, along with expanding reimbursement and clinical adoption, will support ongoing commercial momentum.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL3vVLPf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","BK4585","LU0314104364.USD","NDAQ","IE00BKPKM429.USD","BK4112","LU2210149790.SGD","LU2095319765.USD","NRXS","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2588272280","title":"Neuraxis Inc:  Co Expects Va Award to Support Sustained Commercial Momentum Entering 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588272280","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588272280?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA7DKZGJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2588242157","title":"Neuraxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients With Functional Abdominal Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2588242157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588242157?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA7DKZGJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2582167374","title":"Neuraxis announces new medical policy coverage in Michigan","url":"https://stock-news.laohu8.com/highlight/detail?id=2582167374","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582167374?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:31","pubTimestamp":1762954285,"startTime":"0","endTime":"0","summary":"NeurAxis (NRXS) announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation, PENFS, representing approximately 566,00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuraxis-announces-new-medical-policy-coverage-in-michigan-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuraxis-announces-new-medical-policy-coverage-in-michigan-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2582311805","title":"NeurAxis, Inc. Earnings Call: Growth Amid Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2582311805","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582311805?lang=en_us&edition=fundamental","pubTime":"2025-11-12 08:31","pubTimestamp":1762907504,"startTime":"0","endTime":"0","summary":"NeurAxis, Inc. (($NRXS)) has held its Q3 earnings call. Read on for the main highlights of the call. NeurAxis, Inc. recently held its earnings call...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuraxis-inc-earnings-call-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuraxis-inc-earnings-call-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2582161365","title":"NeurAxis Inc. reports third quarter revenue up 22% to $811,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2582161365","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582161365?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:00","pubTimestamp":1762862450,"startTime":"0","endTime":"0","summary":"NeurAxis Inc. reported third quarter 2025 revenues of $811.0 thousand, representing a 22.0% increase compared to $667.0 thousand in the same period last year. Operating loss rose by 27.0% year over year, attributed to increased sales and marketing efforts. The company's cash balance was $4.4 million as of September 30, 2025, with an additional $2.8 million secured in October through an at-the-market equity offering and warrant exercises. Key business developments include upcoming implementation of a CPT Category I code for IB-Stim effective January 1, 2026, expanded FDA clearance for IB-Stim to treat functional dyspepsia and nausea in patients eight years and older, and the inclusion of NeurAxis's PENFS technology in leading clinical practice guidelines.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL5LT1Gz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","NRXS","LU2210149790.SGD","BK4082","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2582936549","title":"Press Release: NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2582936549","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582936549?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:00","pubTimestamp":1762862400,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., Nov. 11, 2025  -- NeurAxis, Inc.  , a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the third quarter period ended September 30, 2025.-- Revenues increased 22% year over year to $811 thousand in 3Q25 compared. -- Operating loss in 3Q25 increased 27% year over year compared to 3Q24 due. -- Cash balance was $4.4 million as of September 30, 2025. Subsequently, the. equity offering and warrant exercises in October 2025.-- Awarded first ever FDA clearance for the treatment of pain in Functional. Dyspepsia  with associated nausea symptoms in the adult patient. recommended in the pediatrics guidelines, enabling momentum for. Brian Carrico, Chief Executive Officer of NeurAxis, commented: \"We remain highly optimistic as we lay the foundation for what we expect will be a major scaling phase in 2026. The years of work to secure the CPT Category I code and expanded insur","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","TM","03160","BK4215","BK4099","BK4585","BK4082","NRXS","CPT","BK4604","BK4588"],"gpt_icon":0},{"id":"2582386700","title":"Neuraxis Q3 EPS $(0.24) Misses $(0.17) Estimate, Sales $811.414K Miss $1.000M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582386700","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582386700?lang=en_us&edition=fundamental","pubTime":"2025-11-11 06:53","pubTimestamp":1762815216,"startTime":"0","endTime":"0","summary":"Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 4 percent increase over losses of $(0.25) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48769505/neuraxis-q3-eps-0-24-misses-0-17-estimate-sales-811-414k-miss-1-000m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Neuraxis Q3 EPS $(0.24) Misses $(0.17) Estimate, Sales $811.414K Miss $1.000M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS"],"gpt_icon":0},{"id":"2582808726","title":"Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), NeurAxis, Inc. (NRXS) and Celcuity (CELC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582808726","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582808726?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:30","pubTimestamp":1762788637,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Allogene Therapeutics (ALLO – Research Report), Neur...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-allogene-therapeutics-allo-neuraxis-inc-nrxs-and-celcuity-celc-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-allogene-therapeutics-allo-neuraxis-inc-nrxs-and-celcuity-celc-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","XBI","BK4082","NRXS","LABU","BK4505","BK4137","LU0029874061.USD","BK4585","BK4588","HCSG","CELC","BK4581","ALLO","BK4139","XLV"],"gpt_icon":0},{"id":"2580732622","title":"NeurAxis Inc. to Release Third Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2580732622","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580732622?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:30","pubTimestamp":1762263012,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDLXSND7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4588","IE00B64PRP62.GBP","BK4082","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","IE00BKPKM429.USD","BK4585","BK4112","NRXS"],"gpt_icon":0},{"id":"2577516831","title":"Neuraxis received FDA 510k clearance for PENFS technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2577516831","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577516831?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:11","pubTimestamp":1761307888,"startTime":"0","endTime":"0","summary":"NeurAxis (NRXS) announced that it has received FDA 510(k) clearance for its proprietary percutaneous electrical nerve field stimulation, PENFS, tec...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuraxis-received-fda-510k-clearance-for-penfs-technology-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuraxis-received-fda-510k-clearance-for-penfs-technology-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2577515880","title":"NeurAxis Wins FDA Clearance for First Adult Functional Dyspepsia Pain Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2577515880","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577515880?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:00","pubTimestamp":1761307210,"startTime":"0","endTime":"0","summary":"NeurAxis Inc. has received FDA 510 clearance for its proprietary percutaneous electrical nerve field stimulation  technology to treat functional abdominal pain associated with functional dyspepsia, including related nausea symptoms, in patients aged 8 years and older. This marks the first FDA clearance for a treatment targeting functional dyspepsia pain in adults. The expanded indication follows a review of clinical data supporting PENFS's safety and efficacy in younger patients, with the FDA extrapolating these findings to adult populations. The clearance significantly broadens NeurAxis's total addressable market and will allow use of the upcoming Category I CPT code for PENFS procedures starting January 1, 2026. No other organizations were mentioned as recipients of this regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL98MMGn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","BK4585","BK4082","LU2095319765.USD","LU2210150020.SGD","NDAQ","NRXS","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","BK4588","LU0314104364.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2577047513","title":"Neuraxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) With Associated Nausea Symptoms in the Adult Patient Population","url":"https://stock-news.laohu8.com/highlight/detail?id=2577047513","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577047513?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:00","pubTimestamp":1761307200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nTUAKSYQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2577534729","title":"NeurAxis Inc. reports $0.8 million net sales and $2.1 million operating loss for Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2577534729","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577534729?lang=en_us&edition=fundamental","pubTime":"2025-10-24 05:28","pubTimestamp":1761254910,"startTime":"0","endTime":"0","summary":"NeurAxis Inc. reported preliminary unaudited financial results for the quarter ended September 30, 2025. The company expects cash and cash equivalents of approximately $4.4 million as of September 30, 2025. Preliminary net sales for the three months ended September 30, 2025 are expected to be approximately $0.8 million, with gross profits of about $0.7 million and an operating loss of around $2.1 million. For the nine months ended September 30, 2025, preliminary net sales are expected to be about $2.6 million, compared to approximately $1.9 million for the same period in 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL1Kh3zF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2570019702","title":"Craig-Hallum Reaffirms Their Buy Rating on NeurAxis, Inc. (NRXS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2570019702","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570019702?lang=en_us&edition=fundamental","pubTime":"2025-09-25 22:55","pubTimestamp":1758812138,"startTime":"0","endTime":"0","summary":"In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on NeurAxis, Inc.. The company’s shares opened today at $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-neuraxis-inc-nrxs-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-neuraxis-inc-nrxs-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXS"],"gpt_icon":0},{"id":"2564007358","title":"NeurAxis Inc. Announces $3.3 Million At-The-Market Offering Agreement with Craig-Hallum Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2564007358","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564007358?lang=en_us&edition=fundamental","pubTime":"2025-09-02 21:15","pubTimestamp":1756818959,"startTime":"0","endTime":"0","summary":"NeurAxis Inc. has announced the execution of a new At The Market Offering Agreement with Craig-Hallum Capital Group LLC, allowing the company to sell shares of its common stock valued at up to $3.3 million. Under this agreement, NeurAxis will leverage Craig-Hallum as its sales agent, utilizing their commercially reasonable efforts to sell the stock based on the company's instructions. This offering is integrated with NeurAxis's existing Registration Statement on Form S-3, which was declared effective earlier this year. The sales agent will earn a 3% commission on gross sales proceeds, and NeurAxis will cover specific legal fees and expenses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content use","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL6H9gJ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NRXS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://neuraxis.com","stockEarnings":[{"period":"1week","weight":0.0635},{"period":"1month","weight":0.2723},{"period":"3month","weight":0.3926},{"period":"6month","weight":0.7545},{"period":"1year","weight":0.6093},{"period":"ytd","weight":0.0705}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. NeurAxis, Inc. was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is based in Versailles, Indiana.","exchange":"AMEX","name":"Neuraxis, Inc.","nameEN":"Neuraxis, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neuraxis, Inc.(NRXS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neuraxis, Inc.(NRXS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neuraxis, Inc.,NRXS,Neuraxis, Inc.股票,Neuraxis, Inc.股票老虎,Neuraxis, Inc.股票老虎国际,Neuraxis, Inc.行情,Neuraxis, Inc.股票行情,Neuraxis, Inc.股价,Neuraxis, Inc.股市,Neuraxis, Inc.股票价格,Neuraxis, Inc.股票交易,Neuraxis, Inc.股票购买,Neuraxis, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neuraxis, Inc.(NRXS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neuraxis, Inc.(NRXS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}